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91. ABSTRACT
Insulin-like growth factor binding protein-1 (IGFBP-1) belongs to a family of soluble
IGFBPs which bind insulin-like growth factors  and modulate their biological actions.
Insulin down-regulates the IGFBP-1 production in the liver. The aim of the study was to
examine  the genetic influence on the regulation of the IGF system and the relation of
circulating IGFBP-1 to cardiovascular risk factors, cardiovascular mortality, insulin secre-
tion, and insulin sensitivity.
The magnitude of the genetic component in the variation of IGF-I, IGF-II, IGFBP-1,
and IGFBP-3 in serum was assessed in twin pairs. No significant heritability was found for
the IGFBP-1 concentrations. A negative correlation was found between serum IGFBP-1 and
late-phase insulin secretion, and a positive correlation between IGFBP-1 and insulin-
stimulated glucose uptake. Cross-twin cross-trait correlations between IGFBP-1 and
insulin secretion were higher in monozygotic than dizygotic twins. No difference was seen
between monozygotic twins and dizygotic twins in the correlation between IGFBP-1 and
insulin-stimulated glucose uptake. In conclusion, serum IGFBP-1 is associated with insulin
secretion and insulin sensitivity and appears to be regulated mainly by environmental
factors. In addition  a latent, possibly genetic, influencing factor may be shared by IGFBP-
1 and late-phase insulin secretion but not by IGFBP-1 and insulin sensitivity.
Insulin resistance is thought to be the underlying abnormality leading to clustering of
cardiovascular risk factors, i.e., glucose intolerance, hypertension, decreased serum high-
density lipoprotein cholesterol, and elevated triglyceride concentration. Insulin resistance
is counterbalanced by increased insulin secretion, which reduces hepatic IGFBP-1 produc-
tion. In our cross-sectional analysis, we showed that low serum IGFBP-1 is associated with
a cluster of cardiovascular risk factors. Low serum IGFBP-1 is obviously another sign of the
metabolic syndrome. In the follow-up study, we unexpectedly found out that it was not the
men with low IGFBP-1 who carried the highest risk for cardiovascular death. Men with high
serum IGFBP-1 had an increased risk for coronary heart disease, cardiovascular and total
mortality.
2. INTRODUCTION
Insulin-like growth factors (IGF I and IGF II) are polypeptides that participate in the growth
and function of almost every organ in the body. The IGFs bear marked structural homology
with insulin and proinsulin and exert growth-promoting, differentiative, and insulin-like
metabolic effects (Froesch et al. 1985). Serum and tissue concentrations of IGF-I are
regulated by growth hormone, nutritional status, age, and other factors (Baxter 1986). The
stability, availability, and bioactivity of  circulating IGFs are regulated by their receptors
(Rechler and Nissley 1990) and binding proteins (Shimasaki and Ling 1991).
Serum insulin-like growth factor binding protein-1 (IGFBP-1) binds both IGFs and
modulates their actions. Insulin down-regulates the production of IGFBP-1 in the liver
(Suikkari et al. 1988), which is the major organ contributing to the circulating IGFBP-1
pool. The aim of the study was to examine the genetic influence on the regulation of serum
IGF system and the the relation of circulating IGFBP-1 to cardiovascular risk factors,
cardiovascular mortality, insulin sensitivity, and insulin secretion.
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3. REVIEW OF THE LITERATURE
3.1. INSULIN-LIKE GROWTH FACTORS
Three different observations led to the discovery of insulin-like growth factors I and II. In
1957, Salmon and Daughaday demonstrated that growth hormone (GH) had no direct
metabolic effect on skeletal tissue but induced factors in serum that mediated its metabolic
effects. These factors were first called sulfation factors, according to their ability to stimulate
the incorporation of radio-labeled sulfate into costal cartilage of hypophysectomized rats.
The term somatomedins, mediators of somatotropin action, was introduced by Daughaday
et al. in 1972. Other investigators found factors in serum that could exert insulin-like effects
on tissues but could not be suppressed by the addition of anti-insulin antiserum, called
nonsuppressible insulin-like activity NSILA-I and -II (Froesch et al. 1967). These substan-
ces were later renamed IGF-I and IGF-II (Rinderknecht and Humbel 1976). Purification
and amino acid sequence determination of somatomedin-C (Klapper et al. 1983) and its
deaminated form somatomedin-A (Enberg et al. 1984), have shown that they are identical
to IGF-I. Several factors in serum have proliferative effect in cell cultures. One of them
purified in a rat liver cell culture medium, has multiplication-stimulating activity (MSA),
(Dulak and Temin 1973; Moses et al. 1980). MSA has 93% homology with human IGF-II
(Rinderknecht and Humbel 1978b; Marquardt et al. 1981).
Structure and synthesis
IGF-I consists of 70 amino acids and has a molecular weight of 7649 D. It has 62% homology
with IGF-II, which has 67 amino acids and a molecular weight of 7471 D. Substantial
structural homology exists between the two IGFs and proinsulin: 20 of insulin´s 52 amino
acids are identical to IGF-I and IGF-II. (Rinderknecht and Humbel 1976; 1978a,b)
IGF-I and IGF-II are products of single genes localized on the long arm of chromosome
12 and on the short arm of chromosome 11, respectively (Brissenden et al.1984; Tricoli et
al. 1984). The IGF-II gene is contiguous with the insulin gene (Bell et al. 1985). Although
the liver accounts for most of the circulating IGFs in adults, virtually all human tissues have
been shown to synthesize IGF-I and IGF-II at some point during pre- or postnatal
development (Rechler and Nissley 1990).
IGF Receptors
The IGFs exert their effects by binding to cell surface receptors. Two subtypes of IGF
receptors have been identified. Type I IGF receptor is a glycoprotein which consists of two
extracellular ligand-binding alpha subunits (125 kD) and two transmembranal beta
subunits (95 kD) with intrinsic tyrosine kinase activity. Type I receptor has a high affinity
for IGF-I and IGF-II but a much lower affinity for insulin (Rechler and Nissley 1985; Ullrich
et al. 1986). Type II IGF receptor is a large monomeric  transmembrane 250-kDa protein
with a short sytoplasmic domain which lacks kinase activity (Morgan et al. 1987). IGF-II
binds with high affinity to type II receptor, whereas IGF-I binds less avidly. Insulin has no
affinity to type II receptor. Both type I and II receptors have been identified in a wide variety
of tissues and cell cultures (Baxter 1986).
Biological effects and regulation
The IGFs act in an endocrine, paracrine, and autocrine manner in many tissues (Underwood
et al. 1986a).The metabolic effects of IGFs are similar to but milder than the actions of
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insulin in insulin target tissues (Froesch et al, 1985). These effects are mediated through
insulin receptors in adipose tissue and through type I IGF receptor and insulin receptors in
skeletal muscle cells. Long-term effects of IGFs on cell differentation and proliferation are
mediated mainly through type II IGF receptors (Froesch et al. 1985). Effects of IGFs on cell
replication and DNA synthesis have been demonstrated in many cell types (Froesch et al.
1985; Baxter 1986). IGF-I mediates the mitogenic actions of GH to cartilage tissue
(Daughaday et al. 1972).
Serum IGF-I level is dependent on age. Levels are low at birth, rise progressively during
childhood, and peak during midadolescence (Hall and Sara 1984). After adolescence, IGF-
I concentrations fall (Clemmons and Van Wyk 1984). Serum IGF-II concentration reaches
adult levels in early childhood and changes little with advancing age (Zapf et al. 1981).
Serum IGF-I and IGF-II levels show no marked diurnal variation (Horner et al. 1981).
The association between GH and serum IGF-I level was one of the first clinical
observations about these growth factors. GH deficiency is associated with a low serum IGF-
I concentration. After intramuscular GH injection, there is an increase in serum IGF-I in
GH-deficient patients as well as normal adults (Clemmons and Van Wyk 1984). Acrome-
galy is associated with increased serum IGF-I concentrations (Clemmons and Underwood
1986).
Nutritional intake is an important regulator of IGF-I but not of the IGF-II. The IGF-
I levels are reduced in malnutrition (Underwood et al. 1986b) and in some chronic disorders
such as chronic liver disease and primary hypothyroidism (Baxter 1986). IGF-I concentra-
tion rises during pregnancy (Furlanetto et al. 1978).
 3.2. INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-1
In 1988, insulin-like growth factor binding protein-1 (IGFBP-1) became the first charac-
terized member of a group of structurally related soluble proteins, that specifically bind and
modulate the actions of IGF-I and IGF-II (Brinkman et al. 1988; Lee et al. 1988; Julkunen
et al. 1988).
IGFBP-1 protein structure and gene organisation
The IGFBP-1 amino acid sequence contains 12 N-terminal and 6 C-terminal cysteine
residues that are conserved in other mammalian IGFBP-1 sequences and amongst other
IGFBPs; both of the cysteine-rich regions are required for optimal IGF binding (Brinkman
et al.1988; Julkunen et al. 1988). The nonconserved IGFBP-1 midregion may act as both
a hinge which defines ligand-binding characteristics and as a specific target for protease
activity. (Lee et al. 1993)
The IGFBP-1 protein can be divided into three regions according to cysteine clusters.
Region 1 contains the first 79 residues of human IGFBP-1, including the 12 N-terminal
cysteines, region 2 includes residues 80-144, and region 3 spans residues 145-234
containing the 6 C-terminal cysteines. Region 3 contains an Arg-Gly-Asp (RGD) sequence
which is conserved in rat, cow, and mouse IGFBP-1 (Lee et al. 1997). The RGD sequences
are present in a group of extracellular matrix proteins and mediate binding of these proteins
to specific cell surface receptors known as integrins (Ruoslahti and Pierschbacher, 1987).
IGFBP-1 is secreted as a phosphoprotein (Koistinen et al. 1993) with serine residues at
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positions 101, 169, and 119, serving as  phosphorylation sites (Jones et al. 1993).
The IGFBP-1 gene has been localized to chromosome 7p14-p12 (Alitalo et al. 1989) and
is contiguous with the IGFBP-3 gene (Ehrenborg et al. 1992). The IGFBP-1 gene is 5 kb
long and contains four exons separated with three introns (Cubbage et al. 1989). In human
adults, the IGFBP-1 gene is expressed primarily in the liver (Brinkman et al. 1988),
secretory and decidualized endometrium (Rutanen et al. 1986) and ovarian granulosa cells
(Jalkanen et al. 1989) The IGFBP-1 promoter region  contains a binding site for hepatic
nuclear factor 1 (HNF1), a DNA-binding protein which is  primarily responsible for basal
IGFBP-1 promoter activity in hepatoma cells (Suwanihkul et al. 1990). The promoter
region also includes glucocorticoid responsive elements (GRE1 and GRE2) which confer the
stimulatory effects of glucocorticoids to the IGFBP-1 promoter (Suwanihkul et al. 1994).
The promoter region contains a binding site for hepatic nuclear factor 3 (HNF3). This
element is also called insulin responsive element (IRE) as it confers the inhibitory effect of
insulin on IGFBP-1 promoter activity (Suwanihkul et al. 1994). Proximally in the promoter
region lies a cAMP-responsive element (CRE), which confers cAMP stimulation to the
IGFBP promoter (Suwanihkul et al. 1993).
Regulation of IGFBP-1
Early investigations on human IGFBP-1 plasma levels described rapid daily fluctuations
ranging 10-fold in normal, healthy individuals (Baxter and Cowell 1987). A similar
phenomenon had been described in earlier studies of PP12 (Seppälä et al. 1983). Suikkari
and coworkers (1988) and Brismar and associates (1988) showed that IGFBP-1 levels
inversely correlated with insulin levels in fasting normal  individuals,  as well as in
individuals with disorders of insulin secretion.
IGF-I and IGF-II inhibit IGFBP-1 expression in HepG2 human hepatoma cells, which
possess abundant type I IGF receptors (Grissom et al. 1993), but not in normal human liver
cells in which type I receptors are low or absent (Villafuerte et al. 1992).
Glucocorticoids and cAMP stimulate IGFBP-1 transcription (Unterman et al. 1993),
but these effects are observed only in conditions of low insulin effect (Powell et al. 1993).
Other stimulants include thyroid hormones (Angervo et al., 1993) and epidermal growth
factor (Angervo et al. 1992). Cytokines may alter IGFBP-1 expression. IL-1beta, TNF alpha,
and IL-6 stimulate IGFBP-1 production by HepG2 cells (Samstein et al. 1996).
Regulatory actions of IGFBP-1
IGFBP-1 inhibits IGF-mediated growth and differentiative functions in many tissues.
Numerous in vitro studies have shown that IGFBP-1 inhibits IGF-I-induced cell prolifera-
tion in the ovary (Angervo et al. 1991), osteosarcoma cells (Campbell and Novak 1991),
prostate (Figueroa et al. 1995), and fibroblasts (Okajima et al. 1993). In vivo studies are
consistent with the inhibitory role on IGF-I action. Recombinant IGFBP-1 has been shown
to inhibit somatic growth stimulated by IGF-I and growth hormone in hypophysectomized
rats (Cox et al. 1994). Growth retardation and hyperglycemia has been demonstrated in
transgenic mice that overexpressed IGFBP-1 (Rajkumar et al., 1995). This is not surprising
since IGFBP-1 can bind IGFs with high affinity. However, under some circumstances,
IGFBP-1 may enhance the mitogenic actions of IGF-I (Elgin et al. 1987; Koistinen et al.
1990).
In summary, IGFBP-1 acts as an endocrine factor regulating the bioavailability of IGF-
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I and modulating IGF-mediated tissue metabolism. IGFBP-1 also acts as an autocrine/
paracrine factor and appears to play a crucial role in the female reproductive system (Lee et
al. 1997).
IGFBP-1 measurements
The first quantitative assays for IGFBP-1 were based on the principle of competitive
displacement radioimmunoassay (RIA) (Rutanen et al. 1982). The development of monoclo-
nal antibodies to IGFBP-1 led to the development of the dual-epitope, direct detection assay
in which  the antigen in the standards and unknowns is quantitatively bound to purified
antibody, usually coated to a solid surface, and detected using a second antibody preparation
which binds to a different site, or epitope, on the antigen (Koistinen et al. 1987). The dual-
epitope method can  easily be adapted to automated methods which  employ fluorescent,
electrochemical, or other detection methods (Koistinen et al. 1996).
Serum IGFBP-1 level shows variability inversely related to insulin secretion, and,
therefore, fasting must preceed  any routine IGFBP-1 sampling. A significant correlation
exists between fasting serum IGFBP-1 and the mean of 24 hour IGFBP-1. (Brismar et al.
1995)
3.3. INSULIN-LIKE GROWTH FACTORS AND THEIR BINDING PROTEINS IN HU-
MAN GLUCOSE AND LIPID METABOLISM
Since IGFs exert 5-10% of the insulin-like activity of insulin and circulate at a concentration
of about 1000 greater than insulin, the hypoglycemic potential of serum IGFs is vast. Most
hypoglycemic activity is not expressed, being inhibited by the complexing of IGFs with
IGFBP-3 and acid-labile subunit.(Baxter 1995)
Intravenous infusion of recombinant IGF in healthy volunteers suppresses insulin
secretion and increases glucose disposal (Zenobi et al. 1992a). Several studies have de-
monstrated that the administration of rhIGF-I can reduce insulin resistance in healthy
subjects as well as in subjects with severe insulin resistance (Schoenle et al. 1991; Hussain
et al. 1993). Insulin infusion studies show a stimulation of IGF-I production and blocking
of IGFBP-1 production, leading to increased free IGF-I (Brismar et al. 1994). Thus, IGF-
I suppresses insulin secretion and insulin, in turn,  stimulates IGF-I production in the liver.
rhIGF-I has been shown to decrease LDL cholesterol and triglyceride levels in subjects
with type II diabetes (Zenobi et al. 1992b; Schalch et al. 1993).
The effects  of IGF-II on glucose metabolism are not well defined, but animal studies
suggest that it has insulin-like metabolic effects, although with a significantly lower potency
(Burvin et al. 1998). In patients with IGF-II -secreting tumors, hypoglycemia may result from
a failure  of IGFBP-3 to adequately sequester the IGFs. In these patients,  blood glucose levels
correlated positively with IGFBP-3 levels  and inversely with IGFBP-2 (Baxter 1995). Unlike
the other IGF-binding proteins, IGFBP-1 is acutely regulated in circulation, in a manner
consistent with its action as a glucose counterregulator (Baxter  1995).
Early clinical studies on IGFBP-1 indicated insulin dependency (Brismar et al. 1988;
Suikkari et al. 1988). Subsequent investigations confirmed that insulin, via inhibition of
IGFBP-1 transcription, is the primary determinant of IGFBP-1 expression (Lewitt and
Baxter 1989). Insulin infusion studies with concurrent hepatic vein and peripheral vein/
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artery sampling studies in patients with IDDM have shown a complete inhibition of hepatic
IGFBP-1 production in 120 minutes, with a decline seen in 60 minutes (Brismar et al.
1994). Hyperinsulinemic obese subjects had low fasting serum IGFBP-1 concentrations
which were inversely correlated with insulin. The inverse relationship between insulin and
IGFBP-1 was similar in normal, normal-obese, and both obese and non-obese women with
polycystic ovary (PCO) syndrome, indicating that the decreased IGFBP-1 levels seen in
hyperinsulinemic obesity is due to  hyperinsulinemia and not obesity per se. (Conover et al.
1992). It is known that a large number of obese PCO  patients and a significant number of
lean PCO patients are hyperinsulinemic (Morin-Papunen et al, 2000) and insulin resistant
(Dunaif et al., 1989). However, since the  cohort in our cardiovascular studies consists of
elderly men, the literature on metabolic changes in PCOS is not covered in this review.
Hyperinsulininemia and insulin resistance are thought to be major factors in the
pathogenesis of cardiovascular disease, and detection and treatment of these conditions could
have individual and public health benefits.  However, these metabolic abnormalities are
often asymptomatic.
In 1993, the sex hormone binding globulin (SHBG) was suggested as marker for
hyperinsulinemia and/or insulin resistance (Nesttler 1993). SHBG  is a liver-derived protein
regulated by sex steroids, T4, and  insulin. Secretion of insulin to the portal vein exposes the
liver to a high concentration of insulin, and low serum SHBG was reported to correlate with
hyperinsulinemia (Preziosi et al. 1993) and insulin resistance (Birkeland et al. 1993). This
provided a potential explanation for the observation that low serum SHBG was a predictor
for type  II diabetes mellitus (Lindstedt et al. 1991). However, in a prospective study with
760 men and 624 women,  SHBG correlated with heart disease risk factors, but showed no
association with cardiovascular disease or ischemic heart disease mortality over the 19-year
follow-up (Goodman-Gruen 1996).
At the beginning of this study, we hypothetized that IGFBP-1,  produced by the liver
and down-regulated by insulin, could be a marker for hyperinsulinemia and/or insulin
sensitivity. Later, reduced serum IGFBP-1 was shown to predict hyperinsulinism in obese
women without NIDDM (noninsulin-dependent diabetes mellitus) (Mogul et al. 1996). In
1995, an important report was published, in which Yki-Järvinen and her group used an
insulin-clamp protocol  with healthy and IDDM (insulin-dependent diabetes mellitus)
subjects to demonstrate that  hepatic portal insulin concentrations regulate the production
of both SHBG and IGFBP-1 in the liver.  IGFBP-1 and SHBG can therefore be used as
markers of insulin sensitivity  only in individuals with intact insulin secretion. (Yki-
Järvinen et al. 1995)
3.4. INSULIN-LIKE GROWTH FACTORS AND THEIR BINDING PROTEINS IN CIR-
CULATION
Serum IGF concentrations are 10 to 1000-fold higher than those of insulin, but most
circulating IGFs are bound to insulin-like growth factor binding proteins and only about
1-10 % are free (Daughaday and Rotwein, 1989). Such free IGFs , though cleared rapidly,
have the potential to exert as much insulin-like activity as insulin.
IGFBP-1 may have a role in inhibiting free IGF activity.  IGFBP-1 differs from other
IGFBPs,  showing marked diurnal variation due to changing metabolic status. Levels rise
more than 10-fold at fasting and fall after the morning meal (Yeoh 1988). Due to the great
variability in IGFBP-1 levels resulting from its acute metabolic regulation, comparable
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normal ranges in different laboratories have been difficult to  establish (Baxter 1994). Serum
IGFBP-1 concentration declines in adolescence (Argente et al. 1993) and remains low in
adulthood. With advancing age, there may be a slight increase in serum IGFBP-1 as the
inverse correlation with insulin level becomes less pronounced (Rutanen et al. 1993).
Hemodynamic actions of IGF-I
IGF-I has an effect on the regulation of vascular tone, causing an increase in skeletal muscle
blood flow and a decrease in vascular resistance. In animal experiments, IGF-I may have
differential effects in different vascular beds, exerting a vasodilatory effects on rat aortic ring
and vasoconstrictor effects in rat mesenteric artery (Wu et al. 1994). In men recombinant
human IGF-I increases forearm blood flow (Copeland and Nair 1996).
Nitric oxide (NO) in the vascular effects of IGF-I
In 1991,  Haylor and his colleagues demonstrated that nitric oxide synthesis inhibitor
prevented vasodilatation by IGF-I in the rat renal artery. Later, IGF-I was shown to stimulate
NO production in human vascular endothelial cells (Tsukahara et al. 1994) and vascular
smooth muscle cells (Muniyappa et al. 1997). In healthy volunteers, an IGF-I-mediated
increase in forearm blood flow could be blocked by an inhibitor of nitric oxide synthase
(Fryburg 1996). IGF-I has been shown to induce  coronary vasorelaxation (Hasdai et al.
1998).
Administration of recombinant IGF-I
To determine systemic cardiovascular effects in humans, IGF-I has been injected subcuta-
neously into healthy men (Donath et al. 1996). Cardiac function and performance were
evaluated by echocardiography and an exercise test. IGF-I improved cardiac performance
with a significant increase in stroke volume and cardiac output of 14 % and 18 %,
respectively. The ejection fraction increased by 9% after IGF-I treatment. Heart rate was not
significantly increased at rest or during exercise. Systolic blood pressure was slightly
increased by IGF-I, whereas diastolic blood pressure was slightly decreased (Donath et al.
1996). Two years later, the same group published a study with eight patients with chronic
cardiac failure; acute administration of IGF-I in patients with chronic heart failure improved
cardiac performance by afterload reduction and possible positive ionotropic effect (Donath
et al. 1998).
3.5. ATHEROSCLEROSIS AND THE INSULIN-LIKE GROWTH FACTOR AXIS
Although the functions of circulating IGFs have become clearer over the past decade, the
actions of locally produced IGFs are still ill-defined. IGF-I, IGF-II, and their binding
proteins are secreted by cells of the cardiovascular system. IGFs, IGF-binding proteins and
their specific proteases constitute an IGF axis which determines the extent of IGF-dependent
cellular effects (Bayes-Genis et al. 2000). Accumulating evidence indicates that IGFs and
their regulatory proteins, secreted by the cells of the cardiovascular system, are growth
promoters for arterial cells  and mediators of cardiovascular disease ( Cercek et al. 1991; Ferns
et al. 1991; Delafontaine P. 1995; Grant et al. 1996). Atherosclerotic plaque develops over
several decades and involves inflammatory cell infiltration, smooth muscle cell proliferation,
accumulation of extracellular matrix, fibrous cap formation, and angiogenesis (Ross 1999).
Among various growth factors in plaque development, IGFs play a relevant role.  The
different cell types secrete IGFs, and type I IGF receptors are present on smooth muscle cells
(Pfeife et al. 1983), inflammatory cells (Hochberg et al. 1992),  and arterial endothelial cells
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(Bar et al. 1984) within the atherosclerotic lesion.
Activation of vascular smooth muscle cells (VSMCs)
VSMC dysregulation at atherosclerotic sites is associated with a shift from the contractile to
synthetic phenotype  and displays many features of growth factor activation (Bayes-Genis
et al. 2000). Several studies of both animal (Clemmons 1985; Banskota et al. 1989) and
human VSMCs (Grant et al.1994) have shown that IGF-I induces proliferation and
migration of these cells .
Studies in ischemic patients reinforce the IGF effects seen in vitro. Expression of IGF-I,
IGF-I receptor, and IGFBP-1, -2, -3, -4, and -5 has been demonstrated in human coronary
atherectomy specimens (Grant et al. 1996). Inhibition of IGF-stimulated coronary smooth
muscle cell proliferation by the somatostatin analog octreotide has been substantiated
(Grant et al. 1994). Migration of VSMCs from the media is a major pathologic vascular
response leading to development and progression of the atherosclerotic lesions.  IGFs are
potent stimuli for VSMC migration,  and the effect appears to be mediated through type I
IGF receptor (Bayes-Genis  et al. 2000).  Interestingly, IGFBP-1 stimulates migration
independent of IGF-I via the alpha5beta1integrin (Jones et al. 1993).
Little is known about IGFBPs and proteases in atherosclerosis.  IGFBP-2 and IGFBP-
4 are the more prevalent binding proteins secreted by VSMCs (Cohick et al. 1993;
Gockerman et al. 1995). Recently, a novel IGFBP-4-specific protease was isolated and
identified as pregnancy- associated plasma protein-A (Lawrence et al. 1999). By cleaving
IGFBP-4 and releasing free IGF-I, PAPP-A appears to modulate growth in local prolifera-
tive responses (Conover et al. 1993).
Macrophage activation
Macrophage accumulation is an early event in atherosclerosis. Type I receptors on the
macrophage surface allow the IGFs to modulate macrophage concentration at the vessel wall
(Hochberg et al. 1992). Human macrophages also synthesize and secrete IGF-I (Nagaoka et
al. 1990) and some of the binding proteins (Li et al. 1996). IGF-I has been shown to increase
macrophage intake and degradation of low-density lipoprotein (Hochberg et al. 1992).
Angiogenesis
Normal coronary arteries have no vessels within the inner media or intima. Angiogenesis is
regulated by many growth factors including fibroblast growth factor, vascular endothelial
growth factor, transforming growth factor, and IGF-I (Nicosia et al., 1994; Grant et al.,
1993). Endothelial cells possess receptors for IGF-I and secrete IGF-I and IGFBPs (Delafon-
taine P, 1995). IGF-I has an chemotactic action on vascular endothelial cells (Grant et al.,
1987).
Inflammatory angiogenesis occurs in atherogenesis and involves both endothelial cells
and macrophages. Animal studies after microembolisation of coronary artery showed
alterations in gene expression of IGF and the binding proteins 3, 5, and 6 in macrophages
(Kluge et al., 1997).
Restenosis
Coronary restenosis is a major clinical problem after revascularization procedures. Several
studies indicate that IGF-I is involved in local cellular events leading to restenosis after
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angioplasty (Hansson et al., 1987; Cercek et al., 1991). In the early stages of restenosis ,
VSMC IGF-I from human restenotic specimens is much higher than in normal coronary
VSMCs (Grant et al. 1994). In addition, IGF-I appears to have a growth-promoting effect
on VSMCs after balloon injury. VSMC injury has been shown to increase the expression of
PAPP-A, an  IGFBP-4 protease, which in turn releases free IGF-I and appears to be involved
in neointimal hyperplasia (Bayes-Genis  et al.  2001).
3.6. CARDIOVASCULAR RISK FACTORS
The concept of risk factors for coronary heart disease (CHD) was established in the
Framingham Heart Study report in 1961 (Kannel et al. 1961). Hypercholesterolemia,
hypertension, and smoking were identified as major contributors to cardiovascular disease.
These findings were confirmed in the Seven Countries Study (Keys et al. 1966). Later the
effect of high serum cholesterol in atherosclerosis has been shown to be mainly due to LDL-
cholesterol. Research from experimental animals, laboratory investigations, epidemiology,
and genetic forms of hypercholesterolemia indicate that elevated LDL cholesterol is a major
cause of CHD. The relationship between LDL cholesterol levels and CHD risk is continuous
over a broad range of LDL levels, from low to high  (NCEP Expert Panel, 2001).
Epidemiological data consistently show a continous, positive, linear relationship of the
height of both systolic and diastolic blood pressure with the incidence of coronary heart
disease and stroke (Alderman 1993; Hansson et al. 1999).
Cigarette smoking is the third well-established risk factor (Sackett et al. 1968). As
nicotine impairs endothelium-dependent vasodilatation in human vessels (Chalon et al.
2000) and cigarette smoke contains a large number of oxidants (Church and Pryor 1984),
it has been proposed that the effects of smoking may result from oxidative damage to vascular
endothelium (Celermajer et al. 1993).  In a cohort study with 7178 elderly persons (65 years
of age or older), current smoking increased the risk of total, cardiovascular, and cancer
mortality about 2-fold both among men and women (LaCroix 1991).
3.7. INSULIN RESISTANCE AND RISK FACTORS FOR CORONARY
HEART DISEASE
As  the contribution of classical risk factors to coronary mortality is waning , the importance
of obesity, insulin resistence, and NIDDM continues to grow (Braunwald 1997). Insulin
resistance can be defined as a decrease in the effect of insulin to stimulate  glucose uptake.
Postreceptor defects in insulin action lead to compensatory elevation  in insulin secretion and
and common findings in individuals with insulin resistance are elevated fasting, postpran-
dial and post-glucose insulin levels (Laakso 1996). When the pancreas is no longer able to
sustain this compensatory hyperinsulinemia, non-insulin dependent diabetes mellitus with
significant hyperglycaemia develops (Reaven et al. 1988).
The hypothesis that elevated insulin levels might contribute to the risk of atherosclerosis
was first presented by Nikkilä et al in 1965. In 1979, the first prospective study  published
on hyperinsulinemia and coronary heart disaese (Pyörälä 1979) initiated a long-lasting
debate  on the role of hyperinsulinemia in CHD. In 1988, Reaven described  hyperinsuli-
nemia and insulin resistance to cluster with several risk factors, such as with glucose
intolerance, low HDL cholesterol, high total triglycerides, and hypertension, and suggested
that the metabolic and hemodynamic abnormalities associated with insulin resistance play
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a major role in the eathiology of CHD. Since then, abundant data has accumulated in support
of this hypothesis. To emphasize our inadequate understanding of these relationships,
Reaven called the cluster of risk factors syndrome X, which was later  replaced by the term
metabolic syndrome. The metabolic syndrome  is a widespread phenomenon and makes a
major contribution to common and serious diseases. The incidence in the  middle-aged
Finnish population was 17% in men and 8% in women, defined as a clustering of
dyslipidemia (hypertriglyceridemia, low HDL-cholesterol or both) and insulin resistance
(abnormal glucose tolerance, hyperinsulinemia or both).(Vanhala et al. 1997)
Measurement of insulin sensitivity
Assessing peripheral insulin resistence is difficult. The gold standard for assaying insulin
sensitivity has been the euglycemic hyperinsulinemic clamp which involves a constant
insulin infusion while maintaining euclycemia by infusing a variable amount of glucose
(DeFronzo et al. 1979). This method is technically demanding and limits the number of
subjects to be studied. As an alternative methodology, one may use the frequently sampled
intravenous glucose tolerance test. Perhaps the simplest measure of insulin sensitivity is the
ratio of plasma glucose to insulin. The steady-state basal plasma glucose and insulin
concentrations are determined by their interaction in a feedback loop. A computer-based
model (homeostasis model assessment HOMA) has been used to predict the homeostatic
concentrations that arise from varying degrees of beta-cell deficiency and insulin resistance
(Matthews et al., 1985). Hence, a simple but accurate measure of peripheral insulin
sensitivity still awaits discovery.
3.8.  NEW RISK FACTORS
The past decade has been characterized by growing interest in atherosclerosis as an
inflammatory disease  (Ross 1999). Several reports have shown a correlation between
atherosclerosis and Chlamydia Pneumoniae (Libby et al. 1997), which has been identified
in atheromatous lesions of coronary arteries (Jackson et al. 1997). Increased titer of
antibodies  has been used as a predictor of future adverse events in patients who have had a
myocardial infarction (Thom et al. 1991; Gupta 1997). Infection, combined with other
factors, may be responsible for the development of atherosclerotic lesions in some patients.
In a recent report antimicrobial treatment reduced the risk of cardiovascular events in
patients with non-Q-wave infarction or unstable angina (Sinisalo et al.  2002).
Chronic inflammatory responses are often associated with specific types of injurious
agents. Inflammation contributes on several levels to the rupture of   vulnerable atheroscle-
rotic plaques and to the superficial intimal erosion, both of which may be followed by
coronary thrombosis (Libby 2001). Thinning of the fibrous cap is apparently due to the
continuing influx and activation of macrophages releasing metalloproteinases and other
proteolytic enzymes at these sites. These enzymes cause degradation of the matrix, which
may subsequently lead to hemorrhage and thrombus formation (Ross 1999).
A number of inflammatory markers acting independently of myocyte necrosis have been
linked to atherosclerosis and acute coronary syndromes. Of these, the most widely studied
is C-reactive protein.  Elevated levels of C-reactive protein are associated with increased risk
of events across the spectrum of coronary syndrome, independent of the presence or absence
of myocyte necrosis (Morrow et al. 1998). More recently, C-reactive protein has been
implicated as having direct atherothrombotic effects (Pasceri et al. 2000; Zwaka et al. 2001).
Interestingly,  an association between C-reactive protein and features of the metabolic
syndrome has been found (Frohlich et al. 2000; Jonkers et al. 2002) which interrelates
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inflammation, lipids and insulin resistance.
In a recent report,  Bayes-Genis and colleagues (2001) present histologic evidence that
pregnancy-associated protein-A (PAPP-A) is expressed in ruptured but not stable plaques.
Circulating PAPP-A levels were significantly elevated in patients with acute coronary
syndromes. Elevated PAPP-A appeared to identify patients with unstable angina in the
absence of elevated troponin or C-reactive protein levels. It is noteworthy that PAPP-A is
a metalloproteinase. The production of metalloproteinases by macrophage foam cells is
thought to contribute to the rupture of plaques in patients with acute coronary syndromes
(Libby  2001).  PAPP-A also  regulates IGF-I bioavailability through proteolysis of IGFBP-
4.  PAPP-A produced by smooth muscle cells has been shown to increase in the coronary after
angioplasty suggesting a possible role of PAPP-A in neointimal hyperplasia (Bayes-Genis
et al. 2001).
 4. AIMS OF THE STUDY
Insulin resistance is an underlying metabolic abnormality involving clustering of cardiovas-
cular risk factors including hypertension, decreased serum HDL, elevated triglyceride
concentration, and glucose intolerance. Assessing peripheral insulin resistance is difficult.
Insulin resistance is counterbalanced by increased insulin secretion. Previous studies have
shown that insulin inhibits IGFBP-1 production in the liver. With this background, the
present study was undertaken to evaluate serum IGFBP-1 as a possible indicator of  insulin
resistance. We also wished to find out whether cardiovascular risk factors or cardiovascular
events were associated with serum IGFBP-1.
The specific purposes of our study were:
- To assess the magnitude of the genetic component in the variation of circulating levels of the
components of the IGF system (I)
- To study whether serum IGFBP-1 concentration correlates with insulin sensitivity assessed
by the insulin-glucose clamp (IV)
- To investigate whether serum IGFBP-1 level correlates with cardiovascular risk factors (II)
- To examine  whether serum IGFBP-1 predicts cardiovascular mortality (III)
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5. MATERIALS AND METHODS
5.1. SUBJECTS
Table 1. Study subjects
Subjects Age (years)
I 79 twin pairs (32 MZ, 47 DZ) 44-77
II 331 men 70-89
III 622 men 65-84
IV 41 twin pairs  (21 MZ, 20 DZ) 54-72
MZ=monozygotic
DZ=dizygotic
Twins (Studies I and IV)
The Finnish Twin Cohort Study is a program examinig genetic and environmental
determinants of chronic disease and risk factors (Kaprio et al. 1978). For the present study,
twin pairs resident in Helsinki and the surrounding communities, with no known diabetes,
were identified from the Twin Cohort and asked to participate in a study of glucose tolerance.
Seventy-nine twin pairs (32 monozygotic, 47 dizygotic) with a mean age of 65 years were
included in Study I. A subset of these pairs was further asked to participate in a more detailed
study on insulin sensitivity and insulin secretion (Study IV). The final sample size was 41
pairs (21 monozygotic, 20 dizygotic) for the Study IV.
The Seven Countries Study (Studies II and III)
The Seven Countries Study was designed to investigate the incidence of coronary heart
disease and associated risk factors in different countries (Keys et al. 1966). The Finnish part
of this study included two cohorts selected from geographically defined rural areas:
Ilomantsi in eastern Finland (East) and Pöytyä and Mellilä in southwestern Finland (West)
(Karvonen et al. 1967). The original cohorts invited to participate in the study in 1959
consisted of all men living in these areas born in 1900-1919 and included 1711 men. Follow-
up examinations were performed 5, 10, 15, 25 and 30 years later. Of the original 1959 cohort
of 1711 men, 766 were alive in 1984 of which 686 underwent medical examination. Fasting
serum samples were available from 622 men, and these formed the study group in 1984. In
1989, 524 men of the original cohort were still alive and were invited to participate in the
30-year examination. 413 men underwent medical examination. A fasting serum sample
was available from 331 men and these men formed our study group in 1989. The reasons for
nonparticipation included long distance travel, dementia, recent myocardial infarction,
severe arthritis, refusal to participate, and inadequate fasting.
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5.2. STUDY DESIGNS AND LABORATORY ANALYSES
Study I
Serum samples were obtained from the subjects after overnight (more than 8 h) fasting and
stored at -20° C until tested. IGF-I was measured using RIA Kits from INCSTAR
Corporation (Stillwater, MN, USA). The assay employs acid treatment and ODS-silica gel
extraction to dissociate IGF-I from its binding proteins. This method had a sensitivity of 2.0
nmol/L and the intraassay coefficient of variation (SD/mean) was 10% at the level of 13 nmol/
L.
Monoclonal antibody against recombinant hIGF-II (Austral Biologicals, San Ramon,
CA) was generated essentially as described earlier for another protein (Koistinen et al. 1994).
IGF-II was measured by a competitive immunofluorometric assay using immobilized
monoclonal anti-IGF-II antibody and Europium-labeled recombinant human IGF-II. IGF-
II was labeled with the Delfia Eu-labeling reagent (Eu-chelate of isothiocyanatobenzyl-
diethylene-triaminetetraacetic acid, Wallac, Turku, Finland). For solid-phase coating,
rabbit antimouse immunoglobulins (Dakopatts Glostrup, Denmark), 2 µg/200 µL Tris
buffer (50 mmol/L Tris-HCl, pH 7.7, containing 9 g/L NaCl and 0.5 g/L NaN3 ), were
adsorbed  onto polystyrene microtiter wells (Eflab, Helsinki, Finland) by an overnight
incubation at room temperature. After washing with a washing solution (Tris buffer
containing 0.5 g/L Tween 20), the strips were saturated with 1% bovine serum albumin for
2 h. Monoclonal mouse antihuman IGF-II, clone F69-1F6, 40 ng/200 µL assay buffer (Tris
buffer containing 5 g/L bovine serum albumin, 0.5 g/L bovine gammaglobulin, 2 g/L
diethylenetriaminepentacetic acid and 0.1 g/L Tween 20) were added into the wells and
incubated at room temperature. After 1 h the wells were washed twice with washing
solution. The standards were recombinant human IGF-II diluted in normal horse serum
(Vector Laboratories, Inc., Burlingame, CA, USA) and were extracted like the serum
samples. The IGFs were separated from the IGFBPs by extraction in formic acid: 50 µL
serum and 25 µL 8 mol/L formic acid containing 0.05 % Tween 20 were mixed, and 175 µL
ice cold acetone was added, mixed, and centrifuged at 5000 g at  4° C for 15 min. The
supernatant (200 µL) was transferred to another tube, evaporated under nitrogen for 0.5 h,
then dissolved in 200 µL distilled water and lyophilized. The lyophilized sample was
suspended in 120 µL assay buffer. In the assay, 25 µL sample and 150 µL assay buffer were
added into the antibody- coated microtiter wells, and, after overnight incubation at 4° C,
Europium-labeled IGF-II (2 ng/50 µL) was added to the wells and incubated for another 40
minutes at room temperature. After washing four times, 200 µL enhancement solution (0.1
mol/L acetate phthalate buffer, pH 3.2, containing 0.1 ml/L Triton X-100, 15 µmol/L 2-
naphthoyl trifluoroacetone and 50 µmol/L tri-n-octylphosphine oxide; LKB Wallac, Turku,
Finland) was added. The wells were shaken gently for 2 min and the fluorescence was
measured by the Delfia research fluorometer Model 1234 (LKB Wallac). Sensitivity of the
IGF-II assay was 120 µg/L, intraassay coefficients of variation were 7.2% at  806 µg/L and
8.6% at 406 µg/L, and interassay coefficients of variation were 4.9% at  779 µg/L and 13%
at 379 µg/L. For analytical recovery,  IGF-II was added to serum and four separate extractions
were assayed in duplicate. Analytical recovery was 75-125%. Crossreactivities were tested
with 1 mg/mL of IGF-I (Austral Biologicals), IGFBP-1 (Koistinen et al., 1990), IGFBP-3
(Celtrix Pharmaceuticals Inc., Santa Clara, Ca, USA) and IGFBP-2,-4,-5,-6 (Austral
Biologicals). IGFBPs 1 to 6 and IGF-I  did not crossreact in the IGF-II assay when added
directly to the immunoassay, nor did they affect the IGF-II levels when added to serum
before extraction.The IGF-II standard curve and the dilution curve of extracted serum were
parallel. Normal serum levels of IGF-II were 653±126 µg/lL (Mean±SD, range 353-909
µg|L, n=34).
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The fasting serum IGFBP-1 concentration was determined by a two-site immunofluo-
rometric assay  using two monoclonal antibodies, F34-15C9 and F36-9G3, as described
earlier (Koistinen et al. 1996). The intraassay variation was 3-11%, the interassay variation
was 4-10%, and the sensitivity of the  assay was 0.1 µg/L.
IGFBP-3 was determined from serum samples using monoclonal antibodies (mAb)
generated against recombinant IGFBP-3 E. Coli (Celtrix Pharmaceuticals) (Koistinen et al.
1994). The assay used mAb F42-1B6 as the solid-phase antibody and mAb F41-5C11 as the
Eu-labeled tracer. The intraassay coefficient of variation was 3.6-6.2% and the interassay
coefficient of variation 5.4-11%. The assay had no crossreactions with the other human
IGFBPs or the IGFs .
Study IV
After an overnight fast, blood samples were drawn for the analysis of plasma glucose, serum
insulin, and insulin-like growth factor binding protein-1 concentrations. Height and
weight were recorded and body mass index (BMI) was calculated as weight/height2 (kg/m2).
Waist circumference and hip circumferences were measured. As a measure of abdominal
obesity, waist-hip ratio (WHR) was calculated. Insulin secretion was measured by the use
of an intravenous glucose tolerance test (IVGTT) during which 0.3 g/kg (maximum dose
35g) of 50% glucose was infused intravenously for 2 min and blood samples for the analysis
of plasma glucose and serum insulin were drawn at 0, 2, 4, 6, 8, 10, 20, 30, 40, 50, and 60
minutes. The first-phase insulin secretion (FPI) was calculated as the incremental area under
the insulin curve during the first 10 minutes and the late-phase insulin secretion (LPI) as the
incremental area under insulin curve during the last 50 min of the IVGTT. Whole body
glucose uptake was quantified with a 160-min euglycemic hyperinsulinemic (45 mU/m2)
clamp as previously described (Eriksson et al., 1989). The IVGTT and the clamp were
performed on separate days in 14 MZ and 5 DZ twins and on the same day in 7 MZ and 15
DZ pairs. When done on the same day, the clamp was started 30 min after the end of IVGTT.
Both members in a twin pair participated in the same clamp protocol. Plasma glucose was
measured on duplicates with a glucose oxidase method using a Beckman Glucose Analyzer
II (Beckman Instruments, Fullerton, CA, USA). Serum insulin concentrations were measu-
red by radioimmunoassay (Pharmacia, Uppsala, Sweden) with an interassay CV of 5%.
Serum IGFBP-1 was measured as described previously for Study I.
Studies II and III
The 25-year follow-up study in 1984 and the 30-year follow-up study in 1989 included
questionnaires, physical performance measurements, and laboratory investigations. Glucose
tolerance was tested using a 75-g oral glucose load. In 1984, the participants were requested
to fast for 4 h before arrival. Between 8.00 am and 4.30 pm fasting and  2-h post-load
capillary blood glucose levels were measured by a refractometric method (Glucometer, Miles
Laboratories, Elkhart, IN, USA). In 1989, the test subjects were asked to fast for at least 12
hours, and the test took place between 8.00 and 12.00 am. Blood glucose was measured from
venous plasma using the glucose dehydrogenase method (Glucose Analyzer II, Beckman
Instruments, USA). The individuals were hierarchically classified according to the WHO
criteria for diabetes mellitus and impaired glucose intolerance (WHO 1985). Insulin
analyses were performed using the Pharmacia Diagnostica Phadeseph Insulin RIA kit
(Pharmacia, Uppsala, Sweden) at fasting and 2 h after the glucose load.
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Total and HDL-cholesterol concentrations were analyzed from fresh sera by an enzymatic
method (Monotest, Boehringer Mannheim GmbH, Germany) using an Olli C 3000
photometer (Kone Ltd. Espoo, Finland). HDL was measured after precipitation of VLDL and
LDL by the dextran-magnesium-chloride method (Kostner 1976), and serum triglycerides
after enzymatic hydrolyzation and determination of the liberated glycerol by colorimetry
with commercial agents (GPOPAP method, Boehringer Mannheim GmbH, Germany)
using KONE C automatic discrete analyzer.
The serum samples were kept frozen at -20° C until tested, after establishing that repeat
freezing, thawing, and storage do not affect the IGFBP-1 level (Rutanen et al. 1984). The
IGFBP-1 concentration was determined by a specific immunofluorometric assay using two
monoclonal antibodies, F34-15C9 and F36-9G3 (Koistinen et al. 1996). The sensitivity of
the assay was 0.1 µg/L, intraassay variation 3-11%, and  linear measuring range 0.1-100 mg/
L. The IGF-I concentration was determined by ELISA (Diagnostic Systems Laboratories,
Webster, TX, USA). The inter- and intraassay coefficients of variation were 4.8-8.8% and
4.5-7.1%, respectively. The IGFBP-3 concentration was determined with immunofluoro-
metric assay (Koistinen et al. 1994). Inter- and intraassay coefficients of variation were 4.9-
11% and 3.6-6.2%, respectively, and the detection limit was 0.3 µg/L. Serum insulin, uric
acid, triglyceride, IGF-I, and IGFBP-3 concentrations were determined from the samples
taken in 1989 only.
Mortality data during follow-up (Study III)
Mortality data were systematically collected during periodic visits to the areas and with the
aid of computerized data linkage to the Finnish Death Register. Death certificates and
hospital records were collected for all the men who died after the 25-year follow-up
examination in 1984 until 1.1.1995. The final cause of death was adjudicated by a single
reviewer in order to minimize variability in allocation of the causes of death.  In 1995, the
vital status of all subjects was ascertained through the Finnish Population Registry. In
addition, for the study population, all hospital discharge diagnoses with ICD-8 codes 410-
414 and 424-440 were identified from the National Hospital Discharge Register, and
hospital records were collected and reviewed. The coder of causes of death was blind to the
risk factor status of the subject. Where multiple causes of death were recorded, priority was
given to accidents, advanced-stage cancer, CHD, stroke, and other conditions as listed. The
basic coding was carried out using the Eighth Revision of the WHO International
Classification of Diseases (WHO 1967), but later, internal study codes were amplified for
a more compact classification (Keys et al., 1966). As outcome parameters, we used total,
cardiovascular, and coronary heart disease mortality.
5.3 STATISTICS
Study I
The results are expressed as mean±SD. For IGFBP-1, logarithmic transformation was
carried out before statistical analyses to correct for  skewness. Statistical analyses were based
on standard methods used for twin data. To estimate genetic and environmental components
of variance of the traits, standard univariate twin analyses were carried out (Williams et al.,
1992). These included the test of homogeneity of the mean values and variances across the
twin type. Maximum likelihood analyses based on sample covariance matrices were used to
estimate the components of variance (Neale and Cardon, 1992; Williams et al., 1992).
24
Study II
The results are expressed as mean±SD. Pearson correlation coefficients between IGFBP-1,
IGFBP-3, IGF-I, and a large number of cardiovascular risk factors and parameters of insulin
resistance syndrome were calculated. Although the distribution of some variables was
slightly skewed to the right, logarithmic transformation did not improve the fit, and
therefore, the original measured values were used for the statistical analyses. Significance was
assumed when two-sided p<0.05. Statistical analyses were performed with the SAS
statistical software.
Study III
Serum IGFBP-1 levels in 1984 and 1989 were divided into quartiles. High serum IGFBP-
1 (≥75th percentile) was entered as a dummy variable (with the three lowest quartiles serving
as the reference group) into forced logistic regression models. Age and other coronary risk
factors (weight, BMI, smoking, systolic blood pressure, hypertension, antihypertensive
treatment, serum cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, impaired
glucose tolerance, diabetes, fasting serum insulin) were also included in the models as
covariates. The risk factor-adjusted risk ratios were estimated as the antilogarithm of
coefficients from multivariate models. The 95% confidence intervals were estimated based
on the assumption of asymptotic normality of the estimates.
Study IV
Data are expressed as mean±SD. Insulin and IGFBP-1 values were log-transformed because
of their skewed distribution. Intraclass correlation coefficients (intraclass r)  were calculated
using residuals of trait values after adjustment by linear regression of age and sex. Differences
between zygosity groups were calculated with two-tailed T-test. Pearson´s correlation
coefficients were calculated for the phenotypic correlation using a SOLO statistical package
(Biomedical Data Processing, Los Angeles, CA, USA). The influence of interdependence of
the twin pair members in the estimation of the significance of cross-twin cross-trait-
correlation was controlled for by using methodologies for clustered data, included in the
Stata7-statistical package (Stata Corporation, TX, USA).
5.4. ETHICAL ASPECTS
All subjects had given their informed consent, and the study designs were approved by the
local Ethics Committees Review Boards.
6. RESULTS
6.1. IGF-I, IGF-II, IGFBP-1, AND IGFBP-3 IN TWINS (I)
A total of 32 monozygotic (MZ) and 47 same-sex dizygotic (DZ) twin pairs were included,
of which 42 were female and 37 male pairs. Women had higher IGF-II levels than men,
653±175 vs 522±144 µg/L(mean±SD), respectively (p=0.0001). The IGFBP-3 levels were
also significantly higher in women compared to men (5441±1018 vs 4496±1084 µg/L,
p=0.001).  The differences  remained significant after  adjustment for age. IGF-II and
IGFBP-3 values were adjusted for gender and age prior to the twin analyses. The intrapair
correlations for the IGF-I levels were r=0.41( p=0.009) for  MZ twins and r=0.12 (p=0.22)
for DZ twins of the same sex . The intrapair correlation for the  IGF-II concentration  was
r=0.66 (p=0.0001) for  MZ twins and r=0.34 (p=0.01) for same-sex  DZ twins. The
correlations for the IGFBP-3 levels were r=0.65 (p=0.0001) for MZ pairs and r=0.23
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(p=0.06) for DZ pairs of the same sex. No significant intrapair correlations were found for
the IGFBP-1 concentrations in MZ twins r=0.12 (p=0.2) or DZ twins r=0.18 (p=0.1). The
estimated heritability,  i.e., the proportion of variance attributable to genetic effects in the
best fitting AE-model was 38% for the IGF-I concentration, 66% for the IGF-II concent-
ration, and 60% for the IGFBP-3 concentration. For all three traits, the E model fitted the
data poorly (p>0.05), and additional parameters (D or C) did not improve the model fit. No
significant heritability was found for  IGFBP-1 concentrations.
6.2. IGFBP-1, INSULIN SENSITIVITY AND INSULIN SECRETION IN TWINS (IV)
No correlation was present between IGFBP-1 and first-phase insulin secretion, whereas an
inverse correlation between IGFBP-1 and late-phase insulin secretion was found (r=-0.39,
p=0.001). The correlation coefficient between IGFBP-1 and LPI was -0.380 for MZ twins
and -0.359 for DZ twins. Serum IGFBP-1 correlated positively with insulin-stimulated
glucose uptake (r=0.34, p=0.002). The correlation coefficient was 0.407 for MZ and 0.178
for DZ twins. The cross-twin cross-trait correlations between IGFBP-1 and insulin-
stimulated glucose uptake were similar for MZ (r=0.10; p=0.54) and DZ (r=-0.08; p=0.55)
twins. The cross-twin cross-trait correlation between IGFBP-1 and LPI was higher in MZ
(r=-0.27; p=0.06) than DZ (r=-0.06; p=0.68) twins.
6.3. IGFBP-1 AND CARDIOVASCULAR RISK FACTORS (II)
Fasting serum IGFBP-1 concentration correlated positively with age and HDL-cholesterol.
Negative correlations were found between IGFBP-1 and insulin, BMI,  and serum
triglycerides. For comparison, the correlation coefficients for insulin and cardiovascular risk
factors were calculated. Glucose tolerance was tested in 300 subjects, of whom 48.3%  had
normal glucose tolerance, 19.0% had impaired glucose tolerance, and 32.7% had diabetes.
In diabetic subjects,  a significant correlation between IGFBP-1 and systolic blood pressure
was found (r=-0.23; p=0.02). No significant correlation was present between IGF-I and any
of the cardiovascular risk factors. Serum IGFBP-3 levels correlated positively with serum
cholesterol and negatively with age, serum insulin, and blood glucose.
The homeostasis model assessment was applied in an attempt to evaluate whether insulin
sensitivity and/or insulin secretion (beta-cell function) were determinants of the serum
IGFBP-1 concentrations. Correlations between serum IGFBP-1 and insulin sensitivity (r=
0.25) and beta-cell function (r=-0.27) were highly significant (p=0.0001 for both).
Consequently, 43 % of the subjects belonging to the lowest quartile of serum IGFBP-1
concentrations could also be assigned to the most insulin-resistant quartile.
6.4. IGFBP-1 AND CARDIOVASCULAR MORTALITY (III)
Of the 622 study participants, 358 died between 1 January , 1984 and 1 January, 1995. A
total of 160 subjects died from cardiovascular disease, with 113 of them being coronary
deaths. A nonlinear association was present between serum IGFBP-1 and total and
cardiovascular mortality, with the highest risk in the highest quartile. Variables associated
with IGFBP-1 and other putative risk factors were entered in multiple regression analysis.
The risk of total and CVD mortality increased with increasing age and smoking. Fasting
serum insulin was not a significant predictor for any of the outcome parameters. Furthermo-
re, the effect of high IGFBP-1 was similar in different categories of glucose tolerance
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irrespective of whether the WHO criteria or the American Diabetes Association criteria were
used. No association was found between IGF-I or IGFBP-3 and any category of mortality.
High serum IGFBP-1 (>75 percentile) in 1984 was associated with increased total mortality
(p=0.0002), cardiovascular mortality (p=0.0009), and coronary heart disease mortality
(p=0.002) during the 5-year follow-up. After age adjustment, high serum IGFBP-1
remained a significant predictor of death from all causes (p=0.007), from cardiovascular
disease (p<0.008), and from coronary heart disease (p=0.01) during the 5-year follow up. In
the 10-year follow-up, high serum IGFBP-1 was predictive of death from all causes
(p=0.008), from cardiovascular disease (p=0.04), and from coronary heart disease (p=0.01).
In the 10 year follow up the trend diminished after adjustment for age but remained
significant for death from coronary heart disease (p=0.04).
7. DISCUSSION
7.1. THE GENETIC AND ENVIRONMENTAL FACTORS IN THE VARIATION OF IGF-
I, IGF-II, IGFBP-1, and IGFBP-3
In the twin population, a substantial genetic contribution responsible for the variation of
circulating levels of IGF-I, IGF-II, and IGFBP-3 was found. The IGF-I and IGFBP-3 levels
are age-dependent. Serum IGF-I and IGFBP-3 concentrations normally increase until
puberty and decrease thereafter (Hall et al. 1984). We found  the intrapair correlation for
the IGF-I levels to be much weaker than  previously reported in children (Kao et al. 1994).
This suggests that age-related factors may affect the expression of the gene. Growth hormone
regulates the IGF-I and IGFBP-3 concentrations in serum. In children, relative body height
is correlated with serum IGFBP-3 levels (Vihervuori et al. 1996). In our study with adult
subjects, no significant correlation existed between IGFBP-3 and height.
As opposed to IGF-I, IGF-II and IGFBP-3, no significant heritability for IGFBP-1
concentrations was found. This is consistent with  IGFBP-1 being involved in rapid
metabolic adaptation to nutritional stimuli. Thus serum IGFBP-1 appears to be regulated
mainly by environmental factors. In a recently published  twin study, by contrast, genetic
variance accounted for more than 60% of the glucose-stimulated insulin secretion and
almost 40%  of  insulin-stimulated glucose uptake (Lehtovirta et al. 2000).
7.2. IGFBP-1, INSULIN SECRETION, AND INSULIN SENSITIVITY
Cross-twin cross-trait correlation coefficients between IGFBP-1 and insulin secretion were
higher in MZ than DZ twins. No difference was seen between MZ and DZ twins in the
correlation between IGFBP-1 and insulin-stimulated glucose uptake. This suggests the
precsence of a latent, possibly genetic, influencing factor shared by IGFBP-1 and insulin
secretion, but not by IGFBP-1 and insulin sensitivity.
Serum IGFBP-1 has been suggested as a useful marker for insulin resistance syndrome
. Our experimental protocol combining an IVGTT with a euglycaemic clamp showed
significant correlations with both insulin sensitivity and late-phase insulin secretion.
However, insulin secretion is dependent upon the degree of insulin sensitivity, and this
study cannot distinguish between the effects of insulin sensitivity and secretion on IGFBP-
1. Yki-Järvinen and co-workers (1995) studied healthy volunteers and IDDM patients and
found that portal insulin rather than insulin sensitivity regulates serum IGFBP-1. They
suggested that IGFBP-1 reflects hepatic insulinisation and may be used as a marker for
insulin sensitivity only in individuals with intact insulin secretion.(Yki-Järvinen et al.
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1995). Using sophisticated methods to measure insulin secretion, impaired insulin secretion
has not been detected until the patients have  impaired glucose tolerance (Eriksson et al.
1989). Insulin resistance is present in the majority of patients with various states of glucose
intolerance, but actual decompensation of glucose homeostasis does not occur if individuals
can maintain a state of compensatory hyperinsulinemia (Weyer et al. 1999). Consequently,
serum IGFBP-1 may be used as a marker of insulin sensitivity in subjects with intact insulin
secretion, and might help in early detection of individuals with insulin resistance.
7.3. IGFBP-1 AND CARDIOVASCULAR RISK FACTORS
The present study on cardiovascular risk factors in elderly men confirmed that the low
fasting IGFBP-1 level is associated with a number of cardiovascular risk factors such as
decreased serum HDL cholesterol, elevated triglyceride concentration, hyperinsulinemia,
and decreased insulin sensitivity. This supports  previous findings by Gibson and co-workers
(1996), who showed that reduced IGFBP-1 levels correlate with low HDL cholesterol, high
insulin, and elevated blood pressure in NIDDM patients. Also in a non-diabetic population,
a positive correlation has been found between IGFBP-1 and HDL cholesterol, and a negative
correlation between IGFBP-1 and insulin (Janssen et al. 1998).
 These findings may be a reflection of insulin resistance and hyperinsulinemia. In the
present work, the correlations between IGFBP-1 and HDL-cholesterol and triglycerides are
less marked than those between insulin and blood lipids. Interestingly, after adjustment for
insulin, the associations between IGFBP-1, HDL and triglycerides failed to retain statistical
significance. As mentioned earlier, the production of IGFBP-1 is suppressed by insulin, and
low serum IGFBP-1 values reflect high insulin values in the circulation and/or the portal
vein.
The observed phenomenon concerning the HOMA estimates can also be explained by
insulin levels, although the HOMA model is dependent on accurate insulin measurements
and cross-reactivity with proinsulin precursors may result in some inaccuracy in HOMA
estimates. One may assume, however, that subjects with low serum IGFBP-1, hyperinsu-
linemia, hypertriglyceridemia and low HDL cholesterol may be insulin-resistant. Therefore,
it is plausible that  a reduced circulating level of IGFBP-1 is associated with a group of factors
that predispose to cardiovascular morbidity (Gibson et al. 1996; Heald et al. 2001).  In
conclusion, low serum IGFBP-1 is found to be associated with an unfavourable cardiovas-
cular risk profile and is another sign associated with the insulin resistance syndrome.
7.3 IGFBP-1 AND CARDIOVASCULAR DEATH
Our studies and other investigations show that low serum IGFBP-1 is associated with an
unfavourable cardiovascular risk profile. Accumulating evidence from the literature indica-
tes that IGFs and their binding proteins are growth promoters for the arterial cells and might
be mediators of cardiovascular diseases (Bayes-Genis 2000). However, no reports are
available on the  association between IGFBP-1 and cardiovascular events. In our 5-year and
10-year follow-ups we found  that high serum IGFBP-1 level (highest quartile) was
associated with increased total, cardiovascular, and coronary heart disease mortality in
elderly men. The finding was quite unexpected and not in line with our previous findings
on the low IGFBP-1 as a sign of unfavourable cardiovascular risk. However, earlier follow-
up studies have demonstrated that  hyperinsulinism may not be associated with the impaired
survival in the aged (Lindberg 1997). After further analyses and discussions, we concluded
that the association between IGFBP-1 and cardiovascular death may be a J-shaped curve.
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Those subjects with low IGFBP-1 die because they have insulin resistance and the associated
traditional cardiovascular risk factors. Subjects with high IGFBP-1 have an even higher risk,
but the mechanism  can only be speculated upon.
Is it through inhibition of IGF-mediated metabolic or mitogenic actions? In our
investigation,  no association was present between cardiovascular mortality and  circulating
IGF-I level. However, we must bear in mind that total IGF-I measured in our study provides
only a crude estimate of the biologically active IGF-I. Administration of human recombi-
nant IGF-I to patients has been demonstrated to  decrease fasting glucose and triglyceride
concentrations and increase insulin sensitivity (Moses et al. 1996). Therefore, one possible
explanation is that high serum IGFBP-1 decreases the amount of unbound IGF-I and
attenuates the known beneficial metabolic effects of IGF-I. This would be in line with the
work of Janssen and co-workers (1998), who reported high free serum IGF-I levels in subjects
with decreased presence of arterosclerotic plaques and signs of coronary heart disease.
However, going back to own results we failed to detect high triglyceride or glucose levels
in the group with high IGFBP-1. Unfortunately, as in many clinical studies on IGFBP-1,
our study focused on circulating levels, and therefore cannot distinguish between the effects
of IGF-I/IGFBP-1 complexes in serum and interstitial fluid and the effects exerted directly
by IGFBP-1.
The IGF axis is complex and many possible interactions account for the functional
diversity the extent of which is only beginning to be understood. Alterations in the balance
of components of the IGF axis in the vessel wall influence the cell growth, survival,
migration, and extracellular matrix synthesis which modulate the atherosclerotic plaque
progression and neointimal formation of restenosis.  Improved insight into the IGF axis
dynamics could identify new targets to limit or prevent vascular pathologies. (Bayes-Genis
A et al., 2000)
A limitation of our study is that our cohort comprised men aged 65-84 years at baseline.
Although those who participated are considered representative of their age group, with a
high participation rate and complete ascertainment of deaths , by definition, they represent
only those men who have survived to old age. Because many cardiovascular events occur at
a younger age, these findings must be confirmed in middle-aged men and women.
Our results indicate that high serum IGFBP-1 is associated with an increased risk of
coronary heart disease, cardiovascular disease, and total mortality in elderly men.   As the
reasons for this observation are not obvious further studies are needed to find determine the
mechanism. Another interesting approach would be to study the effect of cardiovascular
medication, such as statin treatment, on  the components of the IGF axis.
8. CONCLUSIONS
- Serum IGFBP-1 is regulated mainly by environmental factors.
-Serum IGFBP-1 may be used as a marker of insulin sensitivity in subjects with intact insulin
secretion, and might help in the early detection of insulin-resistant individuals.
-Low serum IGFBP-1 is associated with an unfavourable cardiovascular risk profile and is
another sign associated with the insulin resistance syndrome.
-High serum IGFBP-1 is associated with an increased risk of coronary heart disease,
cardiovascular  and total mortality  in elderly men.
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